Prognostic value of neuroendocrine markers for predicting survival in patients with small cell lung cancer

International Journal of Clinical and Experimental Pathology

Volumn 9, Issue 6, 2016, Pages 5970-5979

  Sun, Ruifang ^a,b   Liu, Zhigang ^b   Ma, Gang ^b   Ding, Caixia ^c   Lü, Weidong ^b   Zhang, Juan ^c   Wang, Xiang ^c   Zhou, Dangxia ^a,b  

^a MEDICAL SCHOOL OF XI AN JIAOTONG UNIVERSITY   (China)

^b XI'AN JIAOTONG UNIVERSITY   (China)

^c Tumor Hospital of Shaanxi Province   (China)

Author keywords

CGA; Immunohistochemistry; Neuroendocrine differentiation; Small cell lung carcinoma

Indexed keywords

EID: 84994030688     PISSN: None     EISSN: 19362625     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Siegel R, Naishadham D and Jemal A. Cancer statistics, 2012. CA Cancer J Clin 2012; 62: 10-29.
2. Oser MG, Niederst MJ, Sequist LV and Engelman JA. Transformation from non-small-cell lung cancer to small-cell lung cancer: molecular drivers and cells of origin. Lancet Oncol 2015; 16: e165-172.
3. Ren Y, Hou J, Xu A and Pan Y. Diagnostic utility of PAX2 and PAX5 in distinguishing non-small cell lung cancer from small cell lung cancer. Int J Clin Exp Pathol 2015; 8: 14709-14716.
4. Hartley CP, Steinmetz HB, Memoli VA and Tafe LJ. Small cell neuroendocrine carcinomas of the lung do not harbor high-risk human papillomavirus. Hum Pathol 2015; 46: 577-582.
5. Cheng Y, Sun Z, Bai C, Yan X, Qin R, Meng C and Ying H. Serum chromogranin A levels for the diagnosis and follow-up of well-differentiated non-functioning neuroendocrine tumors. Tumour Biol 2016; 37: 2863-9.
6. Fan S, Hao ZY, Zhang L, Chen XG, Zhou J, Zang YF, Tai S and Liang CZ. Increased chromogranin A and neuron-specific enolase in rats with chronic nonbacterial prostatitis induced by 17-beta estradiol combined with castration. Int J Clin Exp Pathol 2014; 7: 3992-3999.
7. Liao LM, Zhang X, Ren YF, Sun XY, Di N, Zhou N, Pan RK, Ma SH and Zhou LX. Chromogranin A (CgA) as poor prognostic factor in patients with small cell carcinoma of the cervix: results of a retrospective study of 293 patients. PLoS One 2012; 7: e33674.
8. Wang YH, Yang QC, Lin Y, Xue L, Chen MH and Chen J. Chromogranin A as a marker for diagnosis, treatment, and survival in patients with gastroenteropancreatic neuroendocrine neoplasm. Medicine (Baltimore) 2014; 93: e247.
9. Conteduca V, Burgio SL, Menna C, Carretta E, Rossi L, Bianchi E, Masini C, Amadori D and De Giorgi U. Chromogranin A is a potential prognostic marker in prostate cancer patients treated with enzalutamide. Prostate 2014; 74: 1691-1696.
10. Drivsholm L, Paloheimo LI and Osterlind K. Chromogranin A, a significant prognostic factor in small cell lung cancer. Br J Cancer 1999; 81: 667-671.
11. Pujol JL, Quantin X, Jacot W, Boher JM, Grenier J and Lamy PJ. Neuroendocrine and cytokeratin serum markers as prognostic determinants of small cell lung cancer. Lung Cancer 2003; 39: 131-138.
12. Petrovic M, Bukumiric Z, Zdravkovic V, Mitrovic S, Atkinson HD and Jurisic V. The prognostic significance of the circulating neuroendocrine markers chromogranin A, pro-gastrin-releasing peptide, and neuron-specific enolase in patients with small-cell lung cancer. Med Oncol 2014; 31: 823.
13. Adams DJ, Arthur CP and Stowell MH. Architecture of the Synaptophysin/Synapto-brevin Complex: Structural Evidence for an Entropic Clustering Function at the Synapse. Sci Rep 2015; 5: 13659.
14. Ather MH, Abbas F, Faruqui N, Israr M and Pervez S. Correlation of three immunohistochemically detected markers of neuroendocrine differentiation with clinical predictors of disease progression in prostate cancer. BMC Urol 2008; 8: 21.
15. Dorff TB, Liu SV, Xiong S, Cai J, Hawes D and Pinski J. Ethnic differences in neuroendocrine expression in prostate cancer tissue. Antican-cer Res 2011; 31: 3897-3901.
16. Mehrabian M, Brethour D, Wang H, Xi Z, Rogaeva E and Schmitt-Ulms G. The Prion Protein Controls Polysialylation of Neural Cell Adhesion Molecule 1 during Cellular Morphoge-nesis. PLoS One 2015; 10: e0133741.
17. Tajima S and Fukayama M. CD56 may be a more useful immunohistochemical marker than somatostatin receptor 2A for the diagnosis of phosphaturic mesenchymal tumors. Int J Clin Exp Pathol 2015; 8: 8159-8164.
18. Markovic-Lipkovski J, Zivotic M, Muller CA, Tampe B, Cirovic S, Vjestica J, Tomanovic N, Zeisberg M and Muller GA. Variable Expression of Neural Cell Adhesion Molecule Isoforms in Renal Tissue: Possible Role in Incipient Renal Fibrosis. PLoS One 2015; 10: e0137028.
19. Sterlacci W, Fiegl M, Hilbe W, Auberger J, Mikuz G and Tzankov A. Clinical relevance of neuroendocrine differentiation in non-small cell lung cancer assessed by immunohistochemistry: a retrospective study on 405 surgically resected cases. Virchows Arch 2009; 455: 125-132.
20. Jung J, Son YS, Park H, Jeon SK, Lee JW, Choi SY, Kim JM, Kwon YG, Hong HJ and Min JK. The cell adhesion molecule L1 promotes gallbladder carcinoma progression in vitro and in vivo. Oncol Rep 2011; 25: 945-952.
21. Kok-Sin T, Mokhtar NM, Ali Hassan NZ, Sagap I, Mohamed Rose I, Harun R and Jamal R. Identification of diagnostic markers in colorectal cancer via integrative epigenomics and genomics data. Oncol Rep 2015; 34: 22-32.
22. Ceyran AB, Senol S, Simsek BC, Sagiroglu J and Aydin A. Role of cd56 and e-cadherin expression in the differential diagnosis of papillary thyroid carcinoma and suspected follicular-patterned lesions of the thyroid: the prognostic importance of e-cadherin. Int J Clin Exp Pathol 2015; 8: 3670-3680.
23. Hamanaka W, Motoi N, Ishikawa S, Ushijima M, Inamura K, Hatano S, Uehara H, Okumura S, Nakagawa K, Nishio M, Horai T, Aburatani H, Matsuura M, Iwasaki A and Ishikawa Y. A subset of small cell lung cancer with low neuroendocrine expression and good prognosis: a comparison study of surgical and inoperable cases with biopsy. Hum Pathol 2014; 45: 1045-1056.
24. Segawa Y, Takata S, Fujii M, Oze I, Fujiwara Y, Kato Y, Ogino A, Komori E, Sawada S, Yamashita M, Nishimura R, Teramoto N and Takashima S. Immunohistochemical detection of neuroendocrine differentiation in non-small-cell lung cancer and its clinical implications. J Cancer Res Clin Oncol 2009; 135: 1055-1059.
25. Mitsudomi T, Morita S, Yatabe Y, Negoro S, Okamoto I, Tsurutani J, Seto T, Satouchi M, Tada H, Hirashima T, Asami K, Katakami N, Takada M, Yoshioka H, Shibata K, Kudoh S, Shimizu E, Saito H, Toyooka S, Nakagawa K and Fukuoka M. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol 2010; 11: 121-128.
26. Li H, Wang Y, Su F, Li J and Gong P. Monitoring of cyclooxygenase-2 levels can predict EGFR mutations and the efficacy of EGFR-TKI in patients with lung adenocarcinoma. Int J Clin Exp Pathol 2015; 8: 5577-5583.
27. Howe MC, Chapman A, Kerr K, Dougal M, Anderson H and Hasleton PS. Neuroendocrine differentiation in non-small cell lung cancer and its relation to prognosis and therapy. Histopathology 2005; 46: 195-201.